AVEO - AVEO Pharmaceuticals, Inc.
| Previous Close | 0.7034 |
| Open | 0.6967 |
| Bid | 0.6610 x 900 |
| Ask | 0.6899 x 900 |
| Day's Range | 0.6600 - 0.7034 |
| 52 Week Range | 0.4700 - 2.1400 |
| Volume | 1770686 |
| Avg. Volume | 2,120,961 |
| Market Cap | 108M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | 6.61 |
| EPS (TTM) | 0.1020 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.92 |
- Zacks
Why Is AVEO (AVEO) Down 0.1% Since Last Earnings Report?
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
AVEO Oncology (AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®), the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC). The article, titled “Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study”, is available online first via this link.
- TEST Business Wire Releases
AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at 4:30 p.m. Eastern Time.
- Business Wire
AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors
AVEO Oncology (AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and life sciences industries. “It is a pleasure to welcome Scarlett to our Board of Directors,” said Michael Bailey, president and chief executive officer of AVEO.
- Business Wire
AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
AVEO Oncology (AVEO) today announced the presentation of updated data from the Phase 3 TIVO-3 trial. The data were presented on Saturday, November 16, 2019, at the 18th International Kidney Cancer Symposium in Miami, in an oral presentation titled “TIVO-3: A Phase 3 Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC) Overall Survival 2-Year Update” by Sumanta (Monty) Kumar Pal, M.D., Associate Clinical Professor, Department of Medical Oncology and Therapeutics Research, and Co-director, Kidney Cancer Program, at City of Hope Comprehensive Cancer Center. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®), the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), to sorafenib in 350 subjects with highly refractory metastatic RCC.
- Zacks
Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal
Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.
- Zacks
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.
- Business Wire
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the third quarter ended September 30, 2019 and provided a business update.
- Zacks
Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis
Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.
- Zacks
Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus
Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.
- Zacks
Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales
Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.
- Zacks
Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates
Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.
- Business Wire
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML
AVEO Oncology (AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). AVEO will sponsor the CyFi-2 study, which is expected to enroll up to a total of 60 patients with AML who failed induction chemotherapy or who achieved a complete response, but relapsed within one year.
- Zacks
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.
- Zacks
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3
Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.
- Business Wire
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma
AVEO Oncology (AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the Company’s proposal to proceed with a New Drug Application (NDA) for tivozanib. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC). The TIVO-3 trial was designed to address the FDA’s concerns regarding the OS trend in the TIVO-1 trial.
- Zacks
AVEO Pharmaceuticals (AVEO) Earnings Expected to Grow: Should You Buy?
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
AVEO Sees Hammer Chart Pattern: Time to Buy?
AVEO Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
Reata (RETA) Jumps: Stock Rises 5. 6%
Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Zacks
AVEO (AVEO) Upgraded to Strong Buy: What Does It Mean for the Stock?
AVEO (AVEO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire
AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma
AVEO Oncology (AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The Phase 1b portion will evaluate the safety, tolerability, dose limiting toxicity, maximum tolerated dose and preliminary anti-tumor activity starting with 1.0mg of tivozanib for 21 days followed by 7 days rest together with 1500mg of durvalumab every 28 days. Assuming satisfactory completion of the Phase 1b portion of the study, a Phase 2 expansion cohort will enroll at the dose schedule designated in Phase 1b.
- Zacks
Renal Cell Carcinoma Space in Focus: Some Key Developments
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
